Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1985-6-6
|
pubmed:abstractText |
In a double-blind study over a 3-month period, a daily dose of 100 mg ciprofibrate, prescribed in a single administration and a daily dose of 300 mg fenofibrate, prescribed in 3 administrations, significantly reduced the mean values of total cholesterol, LDL cholesterol and VLDL cholesterol, apoprotein B (P less than 0.001) and increased the mean values of HDL cholesterol (P less than 0.01) and total apoprotein A (P less than 0.05). The study, followed-up as an open trial using higher doses (100 or 200 mg/day ciprofibrate, 400 mg/day fenofibrate) tried to demonstrate clearly the benefit of therapy after 9 months with the 2 drugs and to establish the dose-response effects. Comparison of the 2 drugs at the optimal dosages, after 9 months of treatment, showed ciprofibrate to be more effective in increasing HDL cholesterol (P less than 0.05) and apo A (P less than 0.001). No other significant differences in terms of either therapeutic efficacy or biological tolerance became apparent between the 2 drugs. The results obtained in this comparative study were in accordance to those observed in separate trials for ciprofibrate or fenofibrate. Ciprofibrate has the benefit of a long half-life and may also be administered in the form of a single daily dose to patients suffering from major type II hyperlipoproteinaemia.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins A,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins B,
http://linkedlifedata.com/resource/pubmed/chemical/Clofibrate,
http://linkedlifedata.com/resource/pubmed/chemical/Clofibric Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Fenofibrate,
http://linkedlifedata.com/resource/pubmed/chemical/Fibric Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Propionates,
http://linkedlifedata.com/resource/pubmed/chemical/ciprofibrate,
http://linkedlifedata.com/resource/pubmed/chemical/fenofibric acid
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0021-9150
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
54
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
273-81
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:3994783-Adult,
pubmed-meshheading:3994783-Apolipoproteins A,
pubmed-meshheading:3994783-Apolipoproteins B,
pubmed-meshheading:3994783-Clofibrate,
pubmed-meshheading:3994783-Clofibric Acid,
pubmed-meshheading:3994783-Drug Evaluation,
pubmed-meshheading:3994783-Female,
pubmed-meshheading:3994783-Fenofibrate,
pubmed-meshheading:3994783-Fibric Acids,
pubmed-meshheading:3994783-Humans,
pubmed-meshheading:3994783-Hyperlipoproteinemia Type II,
pubmed-meshheading:3994783-Lipids,
pubmed-meshheading:3994783-Lipoproteins,
pubmed-meshheading:3994783-Male,
pubmed-meshheading:3994783-Propionates,
pubmed-meshheading:3994783-Time Factors
|
pubmed:year |
1985
|
pubmed:articleTitle |
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Controlled Clinical Trial
|